替格瑞洛辅助治疗对冠心病经皮冠状动脉介入术后患者凝血功能、血小板聚集率及炎症因子的影响(1)
[摘要]目的 探讨替格瑞洛辅助阿司匹林对冠心病经皮冠状动脉介入术(PCI)患者的凝血功能、血小板聚集率及炎症因子的影响。方法 选取2017年1月～2018年5月我院收治的急诊行PCI的59例冠心病患者作为研究对象，按照随机数字表法将其分为对照组(n=29)与观察组(n=30)。对照组患者接受口服阿司匹林治疗，观察组患者接受替格瑞洛联合阿司匹林口服治疗。比较两组患者治疗前后的凝血功能指标；比较两组患者的血小板聚集率(MPAR)、血栓弹力图(TEG)指标；比较两组患者治疗前后的炎症因子水平及不良反应发生率。结果 治疗后，观察组患者的凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)短于对照组，但凝血酶时间(TT)长于对照组，差异有统计学意义(P<0.05)。观察组患者的MPAR、二磷酸腺苷(ADP)抑制率、花生四烯酸(AA)抑制率低于对照组，K值短于对照组，差异有统计学意义(P<0.05)。治疗后，观察组患者的C反应蛋白(CRP)、白介素-6(IL-6)、髓过氧化物酶(MPO)水平低于对照组，差异有统计学意义(P<0.05)。两组患者的不良反应总发生率比较，差异无统计学意义(P>0.05)。结论 替格瑞洛辅助阿司匹林治疗冠心病PCI有较好的效果，能有效改善术后患者凝血功能，對血小板的抑制效果更强，安全可靠。
[关键词]替格瑞洛；阿司匹林；冠心病；经皮冠状动脉介入术
[中图分类号] R541.4 [文献标识码] A [文章编号] 1674-4721(2019)4(c)-0127-04
Effect of Ticagrelor on coagulation function， platelet aggregation rate and inflammatory factors in patients with coronary heart disease after percutaneous coronary intervention
XU Zuo-heng SU Jian-fen LI Yong-tao YANG Hui
Department of Clinical Pharmacy， Central Hospital in Panyu District of Guangzhou City， Guangdong Province， Guangzhou 511400， China
[Abstract] Objective To investigate the effects of Ticagrelor with aspirin on coagulation function， platelet aggregation，and inflammatory factors in patients undergoing percutaneous coronary intervention (PCI). Methods A total of 59 patients with coronary heart disease who underwent emergency PCI from January 2017 to May 2018 were selected as subjects and were divided into control group (n=29) and observation group (n=30) according to the random number table method. The control group was treated with oral Aspirin， and the observation group was treated with Ticagrelor combined with Aspirin. The coagulation function indexes before and after treatment were compared between the two groups. The platelet aggregation rate (MPAR) and thromboelastogram (TEG) were compared between the two groups. The levels of inflammatory cytokines and the incidence of adverse reactions before and after treatment were compared between the two groups. Results After treatment， prothrombin time (PT) and activated partial thromboplastin time (APTT) in observation group were shorter than those in control group， but thrombin time (TT) was longer than that in control group， the differences were statistically significant (P<0.05). The MPAR， adenosine diphosphate (ADP) inhibitory rate and arachidonic acid (AA) inhibitory rate in the observation group were significantly lower than those in the control group， K value was significantly shorter than that of control group， the differences were statistically significant (P<0.05). After treatment， the levels of C-reactive protein (CRP)， interleukin-6 (IL-6) and myeloperoxidase (MPO) in the observation group were significantly lower than those in the control group， the differences were statistically significant (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion Ticagrelor assisted by Aspirin in the treatment of coronary artery disease after PCI has a better effect， can effectively improve the blood coagulation function of patients after surgery， platelet inhibition effect is stronger， safe and reliable., 百拇医药(徐佐恒 苏健芬 李泳桃)
[关键词]替格瑞洛；阿司匹林；冠心病；经皮冠状动脉介入术
[中图分类号] R541.4 [文献标识码] A [文章编号] 1674-4721(2019)4(c)-0127-04
Effect of Ticagrelor on coagulation function， platelet aggregation rate and inflammatory factors in patients with coronary heart disease after percutaneous coronary intervention
XU Zuo-heng SU Jian-fen LI Yong-tao YANG Hui
Department of Clinical Pharmacy， Central Hospital in Panyu District of Guangzhou City， Guangdong Province， Guangzhou 511400， China
[Abstract] Objective To investigate the effects of Ticagrelor with aspirin on coagulation function， platelet aggregation，and inflammatory factors in patients undergoing percutaneous coronary intervention (PCI). Methods A total of 59 patients with coronary heart disease who underwent emergency PCI from January 2017 to May 2018 were selected as subjects and were divided into control group (n=29) and observation group (n=30) according to the random number table method. The control group was treated with oral Aspirin， and the observation group was treated with Ticagrelor combined with Aspirin. The coagulation function indexes before and after treatment were compared between the two groups. The platelet aggregation rate (MPAR) and thromboelastogram (TEG) were compared between the two groups. The levels of inflammatory cytokines and the incidence of adverse reactions before and after treatment were compared between the two groups. Results After treatment， prothrombin time (PT) and activated partial thromboplastin time (APTT) in observation group were shorter than those in control group， but thrombin time (TT) was longer than that in control group， the differences were statistically significant (P<0.05). The MPAR， adenosine diphosphate (ADP) inhibitory rate and arachidonic acid (AA) inhibitory rate in the observation group were significantly lower than those in the control group， K value was significantly shorter than that of control group， the differences were statistically significant (P<0.05). After treatment， the levels of C-reactive protein (CRP)， interleukin-6 (IL-6) and myeloperoxidase (MPO) in the observation group were significantly lower than those in the control group， the differences were statistically significant (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion Ticagrelor assisted by Aspirin in the treatment of coronary artery disease after PCI has a better effect， can effectively improve the blood coagulation function of patients after surgery， platelet inhibition effect is stronger， safe and reliable., 百拇医药(徐佐恒 苏健芬 李泳桃)